Objective 1: Analyze environment gene interactions (GxA) in a sample of patients with a first psychotic episode, their first-degree relatives and a paired sample of healthy controls.
Objective 2: Apply genetic neuroimaging techniques to assess the association between common variants in candidate genes and genetic variants identified in genome wide association studies (GWAS) and longitudinal structural and functional brain changes in patients with first psychotic episodes. .
Objective 3: To study the longitudinal changes in oxidative stress markers, inflammatory and other biochemical markers in patients with first psychotic episodes and controls by means of the analysis of plasma markers and brain metabolites using magnetic resonance spectroscopy.
Objective 4: Examine the influence of genetic and environmental factors and their interaction on the development, course and prognosis of psychotic disorders.
Objective 5: Examine the symptomatic dimensions affected in psychosis and its stability over time.
Objective 6: To study the influence of GxA interactions on the evolution of cognitive and neurophysiological functioning in patients with first psychotic episodes.
Objective 7: To evaluate the efficacy of a mindfulness-based group intervention to improve social cognition and social functioning in patients with a first episode of psychosis (AGESMind study).
SCIENTIFIC-TECHNOLOGICAL LINES
Neurosciences, Bioinstrumentation, Bioinformatics, Biomedical Engineering and Genotyping, Microarrays and DNA Biochips, applying novel strategies to the study of GxA interactions in schizophrenia.
Internal Documentation
2. PROTOCOL PROCESSING SAMPLES AGES-CM-II (March 2022)
3. PROPOSAL FOR PUBLICATIONS + HISTORICAL PROPOSALS (July 2022)
4. MODEL APPLICATION RM (Fundación Ciën) (June 2019)
5. ALL OPTIONAL MODULES (July 2019)
6. NEW MODEL 2019 PARTICIPANT GIFT CARDS
7. REQUEST MATERIALS (CRD, TARJETAS, TUBOS, etc.)
8. PRESENTATION MANAGEMENT COMITTEE AGES-CM 2 (16-02-2018)
9. GUIDE EXECUTION BMD 2018-2021
10. PUBLICATION MANUAL JOB OFFERS
11. PNT AUTHORIES MANUSCRIPSTS AGES-CM 2 (December 2020)
12. STEERING COMMITTEE 17-12-2020 (December 2020)
13. SCALES TRAINING (February 2021)
14. STEERING COMMITTEE FEBRUARY 2019
15. STEERING COMMITTEE OCTOBER 2021
16. CRD 5 YEARS
Recruitment progress AGES-CM-2 program since February 2018 – October 2021
Photo: 1st Steering Committee Meeting (02-16-2018) AGES-CM 2 (S2017/BMD-3740)
Mental disorders, as a whole, are the leading cause of disability world-wide. In fact, mental health costs represent between 3 and 4% of the gross domestic product in the EU, and mental disorders are the leading cause of early retirement and disability pensions in our society.
In addition, mental diseases take a heavy toll that is not just financial, but also societal, in terms of their burden on individuals and their families. Schizophrenia has been described as the most devastating psychiatric disorder with a prevalence of 1% in the general population. It is estimated that more than 50.000 people in Madrid experience schizophrenia during their lifetime.
The AGES-CM consortium (Ambiente y Genes en Esquizofrenia – Grupos de Investigación de la Comunidad de Madrid) is formed by leading schizophrenia research groups from the Comunidad de Madrid (CM). These research groups from our Community lead the field of schizophrenia research in Spain and at the international level in many aspects of the disease. In fact the most prominent schizophrenia research groups in Madrid are part of the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) that has research on schizophrenia as its highest priority. CIBERSAM constitutes a fully functional ongoing national research program involving numerous schizophrenia research groups.
Supported by the Madrid Regional Government (S2022/BMD-7216 ( AGES 3-CM )) and European Union Structural Funds.
